Notice of intended sale
Open the filing on sec.gov
Immunovant, Inc. (IMVT)
Nasdaq: IMVT · Biological Products, (No Diagnostic Substances) · Durham, NC · filing with the SEC since 2019
The companyfiscal 2026, as filed
Revenuen/a
Net income-$506M-22.2%
Earnings per share$-2.77-1.5%
Operating cash flow-$407M-8.4%
Cash$902M+26.4%
Debtn/a
Shareholders’ equity$853M+20.5%
Shares, diluted182.4M+20.4%
Return on equity-59.3%
The recordfrom its filings
Filings in 202673
Newest filingNov 12 · 144
Annual reportMay 20, 2026
Quarterly reportNov 9, 2026
Next report due10-Q by Feb 9
Insider sales, 12 months$16.6M
Insider buys, 12 months$350M
Patents grantedn/a
Filer categoryLarge accelerated filer
Trailing twelve months to Sep 2026Net income -$509MCash from operations -$395Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Insider trade report
Open the filing on sec.gov
Shelf registration
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Results released
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.